BLFS

Company Overview — What Does BIOLIFE SOLUTIONS INC Do?

BioLife Solutions, Inc. develops, manufactures, and supplies bioproduction tools and services for the cell and gene therapy industry in the United States, Canada, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies. It offers proprietary biopreservation media products, including HypoThermosol FRS and CryoStor that are formulated to mitigate preservation-induced, delayed-onset cell damage and death; and the ThawSTAR line that includes automated vial and cryobag thawing products that control the heat and timing of the thawing process of biologic materials. The company also provides evo shipping containers that are cloud-connected passive storage and transport containers for temperature-sensitive biologics and pharmaceuticals; liquid nitrogen laboratory freezers, cryogenic equipment, and accessories; and biological and pharmaceutical storage services. It markets and sells its products directly, as well as through third party distributors. BioLife Solutions, Inc. was incorporated in 1987 and is headquartered in Bothell, Washington. BIOLIFE SOLUTIONS INC (BLFS) is classified as a small-cap stock in the Healthcare sector, specifically within the Medical Equipment industry. The company is led by CEO Michael P. Rice and employs approximately 440 people, headquartered in Bothell, Washington. With a market capitalization of $932M, BLFS is one of the notable companies in the Healthcare sector.

BIOLIFE SOLUTIONS INC (BLFS) Stock Rating — Avoid (April 2026)

As of April 2026, BIOLIFE SOLUTIONS INC receives a Avoid rating with a composite score of 36.0/100 and 1 out of 5 stars from the Blank Capital Research quantitative model.BLFS ranks #3,944 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, BIOLIFE SOLUTIONS INC ranks #679 of 838 stocks, placing it in the lower half of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

BLFS Stock Price and 52-Week Range

BIOLIFE SOLUTIONS INC (BLFS) currently trades at $19.44. The stock lost $1.04 (5.1%) in the most recent trading session. The 52-week high for BLFS is $29.62, which means the stock is currently trading -34.4% from its annual peak. The 52-week low is $17.86, putting the stock 8.8% above its annual trough. Recent trading volume was 346K shares, suggesting relatively thin trading activity.

Is BLFS Overvalued or Undervalued? — Valuation Analysis

BIOLIFE SOLUTIONS INC (BLFS) carries a value factor score of 33/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth. The trailing price-to-earnings ratio is 1815.00x, compared to the Healthcare sector average of 23.63x — a premium of 7581%. The price-to-book ratio stands at 2.48x, versus the sector average of 2.75x. The price-to-sales ratio is 8.56x, compared to 1.66x for the average Healthcare stock. On an enterprise value basis, BLFS trades at 235.01x EV/EBITDA, versus 6.34x for the sector.

At current multiples, BIOLIFE SOLUTIONS INC trades at a premium to most Healthcare peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.

BIOLIFE SOLUTIONS INC Profitability — ROE, Margins, and Quality Score

BIOLIFE SOLUTIONS INC (BLFS) earns a quality factor score of 36/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is -4.7%, compared to the Healthcare sector average of -43.5%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at -4.3% versus the sector average of -33.1%.

On a margin basis, BIOLIFE SOLUTIONS INC reports gross margins of 64.6%, compared to 71.5% for the sector. The operating margin is -19.0% (sector: -66.1%). Net profit margin stands at -16.9%, versus -58.7% for the average Healthcare stock. Revenue growth is running at -0.9% on a trailing basis, compared to 10.6% for the sector. Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.

BLFS Debt, Balance Sheet, and Financial Health

BIOLIFE SOLUTIONS INC has a debt-to-equity ratio of 1.0%, compared to the Healthcare sector average of 32.0%. The low leverage indicates a conservative balance sheet with significant financial flexibility. The current ratio is 5.94x, indicating strong short-term liquidity. Total debt on the balance sheet is $5M. Cash and equivalents stand at $29M.

BLFS has a beta of 1.40, meaning it is more volatile than the broader market — a $10,000 investment in BLFS would be expected to move 40.4% more than the S&P 500 on any given day. The stability factor score for BIOLIFE SOLUTIONS INC is 46/100, reflecting average volatility within the normal range for its sector.

BIOLIFE SOLUTIONS INC Revenue and Earnings History — Quarterly Trend

In TTM 2026, BIOLIFE SOLUTIONS INC reported revenue of $108M and earnings per share (EPS) of $-0.09. Net income for the quarter was $-17M. Gross margin was 64.6%. Operating income came in at $-20M.

In FY 2025, BIOLIFE SOLUTIONS INC reported revenue of $96M and earnings per share (EPS) of $-0.09. Net income for the quarter was $-5M. Gross margin was 64.6%. Revenue grew 17.0% year-over-year compared to FY 2024. Operating income came in at $-17M.

In Q3 2025, BIOLIFE SOLUTIONS INC reported revenue of $28M and earnings per share (EPS) of $0.01. Net income for the quarter was $621,000. Revenue grew -8.2% year-over-year compared to Q3 2024. Operating income came in at $-89,000.

In Q2 2025, BIOLIFE SOLUTIONS INC reported revenue of $25M and earnings per share (EPS) of $-0.33. Net income for the quarter was $-16M. Revenue grew -10.3% year-over-year compared to Q2 2024. Operating income came in at $-17M.

Over the past 8 quarters, BIOLIFE SOLUTIONS INC has demonstrated a growth trajectory, with revenue expanding from $28M to $108M. Investors analyzing BLFS stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

BLFS Dividend Yield and Income Analysis

BIOLIFE SOLUTIONS INC (BLFS) does not currently pay a dividend. This is common among smaller companies in the Medical Equipment industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.

BLFS Momentum and Technical Analysis Profile

BIOLIFE SOLUTIONS INC (BLFS) has a momentum factor score of 29/100, signaling weak relative price performance. Stocks with low momentum scores have historically tended to continue underperforming in the near term. The investment factor score is 34/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 49/100 reflects moderate short selling activity.

BLFS vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, BIOLIFE SOLUTIONS INC (BLFS) ranks #679 out of 838 stocks based on the Blank Capital composite score. This places BLFS in the lower half of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing BLFS against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full BLFS vs S&P 500 (SPY) comparison to assess how BIOLIFE SOLUTIONS INC stacks up against the broader market across all factor dimensions.

BLFS Next Earnings Date

No upcoming earnings date has been announced for BIOLIFE SOLUTIONS INC (BLFS) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy BLFS? — Investment Thesis Summary

The quantitative profile for BIOLIFE SOLUTIONS INC suggests caution. The quality score of 36/100 flags below-average profitability. The value score of 33/100 indicates premium valuation. Momentum is weak at 29/100, a headwind for near-term performance.

In summary, BIOLIFE SOLUTIONS INC (BLFS) earns a Avoid rating with a composite score of 36.0/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on BLFS stock.

Related Resources for BLFS Investors

Explore more research and tools: BLFS vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare BLFS head-to-head with peers: BLFS vs AZN, BLFS vs SLGL, BLFS vs VMD.